| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| ONCE | Spark Therapeutics, Inc. | $57.05 | $2.14B | N/A |
Michael Porter Jr., once the target for Knicks fans, still isn’t playing much in Denver
http://www.nydailynews.com/sports/basketball/knicks/ny-michael-porter-jr-nuggets-draft-bench-20191206-gtk6l2vmune6tj4qo7lprbqj4e-story.html
Dec 06, 2019 -
On draft night of 2018, the crowd at Barclays Center — of course largely composed of Knicks fans — had their target in mind: Michael Porter Jr.
The former top-ranked forward out of high school, once projected as the No. 1 pick, had fallen because of a serious back injury. And when the Knicks were...
0
What Once Acted As S&P 500 Resistance May Now Act As Support
https://seekingalpha.com/article/4310522-what-acted-s-and-p-500-resistance-may-now-act-support?source=feed_all_articles
Dec 04, 2019 - Noteworthy levels to watch on the S&P 500.Buyers may become more interested near 3,040.If trade hostilities ramp up, the 2,870-2,950 range provides a logical area to watch.
0
Parking Lots, Once Asphalt Wasteland, Become Golden Opportunities
https://www.nytimes.com/2019/12/03/business/parking-lot-death-redevelopment.html?emc=rss&partner=rss
Dec 03, 2019 - As more suburbanites move downtown, developers are seeking new land for housing and offices, creating opportunities for owners of empty parking lots.
0
Is NVIDIA Losing the Plot in This Critical Market Once Again?
https://www.fool.com/investing/2019/11/30/is-nvidia-losing-the-plot-in-this-critical-market.aspx?source=iedfolrf0000001
Nov 30, 2019 - The graphics specialist is finding it difficult to deliver consistent growth in this potentially huge market.
0
Mindy Grossman once shocked her parents by dropping out of college and moving to New York
https://www.cnbc.com/2019/11/28/mindy-grossman-shocked-her-parents-by-dropping-out-of-college.html
Nov 28, 2019 - Shortly before graduating from college, WW CEO Mindy Grossman changed the course of her entire life.
0
Why 'The Mandalorian' episodes are short and arrive on Disney+ once a week
https://www.cnbc.com/2019/11/26/why-the-mandalorian-episodes-are-short-and-arrive-on-disney-once-a-week.html
Nov 26, 2019 - In an era in which binge-watching is the new norm, Disney+ is breaking the mold — at least with its new content.
0
Renowned Tokyo sushi eatery, once frequented by Barack Obama, loses its Michelin 3-star designation
http://www.nydailynews.com/news/world/ny-tokyo-sushi-eatery-loses-michelin-3-star-designation-20191127-kck3ulykrfce7hwxsbfxhknf4a-story.html
Nov 26, 2019 -
Off the hibachi and into the fire.
Sukiyabashi Jiro, one of Tokyo’s most eminent restaurants, has lost its Michelin three-star designation.
The sushi eatery, which had earned the top score annually since 2007, has been dropped from the famous travelers 2020 guide because it doesn’t accept public...
0
Metal Wants to Float, Once It’s Etched With a Fricking Laser
https://www.wired.com/story/floating-metal
Nov 22, 2019 - An absurdly powerful laser can trap an air bubble in a layer of metal, so that it’ll float no matter what.
0
BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A
http://www.zacks.com/stock/news/632905/biomarin-files-maa-to-ema-for-gene-therapy-of-hemophilia-a?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-632905
Nov 22, 2019 - BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
0
Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy
http://www.zacks.com/stock/news/632831/biogen-ends-enrollment-in-eye-disorder-study-on-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-632831
Nov 22, 2019 - Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.
0